Abstract
One of the greatest unmet needs in the treatment of Parkinson's disease (PD) is a disease-modifying therapy, which can halt the ongoing degeneration of dopaminergic neurons that is characteristic of this disorder. Current therapies focus on managing symptoms, rather than on addressing their cause. Promising candidates for disease-modifying therapies are the dopaminergic neurotrophic factors (NTFs). NTFs are secreted proteins which play critical roles in the developing nervous system, directing and supporting the specification, maturation and survival of specific neuronal populations. Several dopaminergic NTFs have shown great potential in animal models of PD, conferring protective and regenerative effects on the nigrostriatal dopaminergic neurons which undergo progressive degeneration in this disease (for reviews see Sullivan and Toulouse, 2011; Hegarty et al., 2014a).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
